D.E. Shaw & Co
PACB icon

D.E. Shaw & Co’s Pacific Biosciences PACB Stock Holding History

D.E. Shaw & Co’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-52,000
Closed -$1.82M – 5151
2021
Q2 		$1.82M Buy
+52,000
New +$1.51M ﹤0.01% 3035

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

D.E. Shaw & Co's PACB Position: Q2 2026 in Review

D.E. Shaw & Co increased its Pacific Biosciences (PACB) stake by 16% in Q2 2026, buying an estimated $830K and bringing the position to 4,208,146 shares worth $7.07M. The position accounts for ﹤0.01% of the portfolio, ranked #2132.

D.E. Shaw & Co first reported a position in PACB in Q2 2013 and has held it in 46 quarters since. The position peaked at $39.5M in Q3 2021. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • D.E. Shaw & Co held 4,208,146 shares of Pacific Biosciences worth $7.07M as of Q2 2026.
  • D.E. Shaw & Co bought 570,599 Pacific Biosciences shares in Q2 2026, an estimated $830K.
  • Pacific Biosciences made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #2132 holding.
  • D.E. Shaw & Co first reported a position in Pacific Biosciences in Q2 2013 and has held it in 46 quarters since.
  • D.E. Shaw & Co's Pacific Biosciences position peaked at $39.5M in Q3 2021.
  • 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.